Treating Cancer With Precision
News
Categories
Sign up
Featured Posts
Archive
Follow Us
- Jul 27, 2021
Meet Alpha Tau at ESTRO 2021 - Cancelled
IMPORTANT UPDATE 22/08/2021 : Unfortunately, due to new measures/circumstances related to the coronavirus (COVID-19), Alpha Tau won’t be attending the ESTRO conference this year.
We sincerely hope to meet you next year! We are pleased to take part in The European Society for Radiotherapy and Oncology (ESTRO)'s annual congress that will be held in Madrid, Spain from 27–31 August 2021. Visit us at our booth 1050.
- Jul 11, 2021
Alpha Tau & Healthcare Capital Corp. to Combine and Create A $1-Billion Publicly Traded Company
Alpha Tau and Healthcare Capital Corp. to Combine and Create A Publicly Traded Company Focused on Transforming the Treatment of Solid Tumors Through the Precision Delivery of Alpha Radiation - Alpha Tau's proprietary Alpha DaRT™ is designed to deliver uniquely potent alpha radiation to destroy solid tumors with localized precision, sparing surrounding healthy tissue, thereby maintaining cancer patients' quality of life. Alpha DaRT™ has recently received FDA's Breakthrough Dev
- Jul 8, 2021
First Alpha DaRT Patient Treated in the US as Part of Pilot Multicenter Skin Cancer Trial
Jerusalem, Israel, July 6, 2021 - Alpha Tau Medical, the developer of the pioneering alpha-radiation cancer therapy Alpha DaRTTM, announced today that the first participant in its US pilot trial for skin cancer has been treated with Alpha DaRT, at University Cancer Center in Houston, Texas. The Houston site, led by radiation oncologist Dr. Mark A. D’Andrea, is part of an expanded multicenter study that originated as a single-center trial at Memorial Sloan Kettering Cancer Cen